Zenith Pharma

Name

Zenith Pharma

Legal name

Zenith Pharma

Website

https://zenithpharma.ma

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Zenith Pharma is a Moroccan pharmaceutical company that develops, in-licenses, and distributes 207 pharmaceutical products across 12 therapeutic categories to healthcare providers, hospitals, and pharmacies across Morocco.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Drug distribution
• Prescription medicines
• Oncology therapeutics

Headquarters

HQ city

Sidi Maarouf

HQ country

Morocco

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical product sales: Zenith Pharma generates revenue through the development, manufacturing, and commercialization of pharmaceutical products across 12 therapeutic categories including cardiology, oncology, neurology, and pediatrics. The company sells both proprietary products and products through partnerships with international pharmaceutical firms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Zenith Pharma develops, manufactures, and commercializes a portfolio of 207 pharmaceutical products across 12 therapeutic categories (musculoskeletal, cardiology, dermatology, gastroenterology, infectiology, oncology-hospital, ophthalmology, pediatrics, pharmacy/OTC, respiratory, central nervous system, and uro-gynecology). The company sells both proprietary in-house branded generics under the Zenith house brand and products through partnerships with leading international pharmaceutical firms, distributing these products to hospitals, clinics, and pharmacies across Morocco.

Product overview

Zenith Pharma is a Moroccan pharmaceutical company established in 2002, serving as a key player in the pharmaceutical industry in Morocco. The company operates as a pharmaceutical distributor and marketer with a broad portfolio of 207 products spanning 12 therapeutic categories: Locomotor (musculoskeletal), Cardiology, Dermatology, Gastroenterology, Infectiology, Oncology-Hospital, Ophthalmology, Pediatrics, Pharmacy (dietary supplements and OTC), Respiratory, Central Nervous System (CNS), and Uro-Gynecology. The portfolio includes both in-house branded products (many carrying the 'Zenith' house brand, such as Imantinib Zenith, Pemetrexed Zenith, Temozolomide Zenith, Ibandro Zenith, Docetaxel Zenith, Anastrozole Zenith, Bicalutamide Zenith, Létrozole Zenith, Donepezil Zenith, and Exemestane Zenith in oncology; Co-Arapro, Co-Zenovan, Co-Iprel in fixed-dose combinations for cardiology) as well as licensed and imported brands (such as Fraxiparine, Halaven, Irinotecan Zenith, Kamagra, Gynoflor, Sensodyne, Parodontax, Physiodose, Physiolac in pediatrics). The company's products range from prescription pharmaceuticals (oncology chemotherapy agents, antipsychotics, antidepressants, anticoagulants, antidiabetics, cardiovascular drugs) to OTC/dietary supplements (Carbozen, Magnezen, Suprabiotique, Multizen, Levure plus). The therapeutic areas are organized into categories on the website and individual product pages provide dosage forms, strengths, and indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Arapro® 150mg Cardiology product, angiotensin II receptor blocker, 150mg dosage, for hypertension treatment.
• Bisocard® 10mg Cardiology product, beta-blocker, 10mg dosage, for cardiovascular conditions.
• Imantinib Zenith® 400mg Oncology hospital product, imatinib mesylate tyrosine kinase inhibitor, 400mg dosage, indicated for Philadelphia chromosome-positive chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal stromal tumors, and related conditions.
• Pemetrexed Zenith® 500mg Oncology hospital product, antimetabolite chemotherapy, 500mg presentation.
• Humorex® 10mg Central nervous system product, escitalopram oxalate SSRI antidepressant, 10mg film-coated tablets.
• Lanzen® 30mg Gastroenterology product, lansoprazole proton pump inhibitor, 30mg extended-release capsules, indicated for duodenal and gastric ulcer, reflux esophagitis, H. pylori eradication, and related acid-related disorders.
• Factive® 320mg Infectiology product, fluoroquinolone antibiotic, 320mg dosage, for infectious disease treatment.
• Acno® 20mg Dermatology product indicated for acne treatment, 20mg dosage.
• Carteol LP® 2% Ophthalmology product, beta-blocker eye drops, 2% concentration, for ocular conditions including glaucoma.
• Physiolac 1® Pediatric product, infant formula stage 1.
• Carbozen® Pharmacy (OTC) product, dietary supplement based on charcoal for digestive comfort, relieving bloating and flatulence; presented as capsules in a box of 60.
• AIRFASTEC Respiratory product for respiratory comfort.
• Gynoflor® 0,03mg/108CFU Uro-gynecology product, vaginal tablets containing estriol and Lactobacillus acidophilus for restoring vaginal flora and treating mild vaginal infections.
• Chondrosulf® 400mg Musculoskeletal product, chondroitin sulfate, 400mg dosage, for joint and cartilage support.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• International pharmaceutical firms (unspecified)coreStrategic or Co-development PartnerZenith Pharma pursues strategic partnerships with the most important global pharmaceutical firms that are leaders in their respective fields. These partnerships enable the company to bring innovative products to the Moroccan market while also developing its own product portfolio.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Cipla: Major Indian generic manufacturer with a strong presence in African markets including oncology, respiratory, and anti-infectives; comparable to Zenith as a generics exporter targeting emerging markets.
• Aspen Pharmacare: Largest African pharmaceutical manufacturer with broad generics, specialty, and OTC portfolios serving sub-Saharan Africa; comparable to Zenith in its African generics manufacturing ambition and broad therapeutic area coverage.
• Sanofi Maroc: Multinational pharma incumbent operating in Morocco across branded specialty and primary care; overlaps with Zenith in therapeutic categories but operates at broader portfolio scale with global R&D backing.

Direct peers

• Galenica Maroc: Moroccan pharmaceutical company with a portfolio of branded generics and specialty products across multiple therapeutic areas; comparable to Zenith in domestic manufacturing scale and hybrid commercial model.
• Laprophan: Established Moroccan pharmaceutical manufacturer with a broad prescription and OTC portfolio serving hospitals and pharmacies across Morocco; directly comparable to Zenith in domestic manufacturing and distribution focus.
• Sothema: Leading Moroccan pharmaceutical manufacturer with a diversified portfolio spanning multiple therapeutic categories including oncology, cardiology, and CNS; directly comparable in scale, market focus, and hybrid own-brand/licensed model.
• Pharma 5: Moroccan pharmaceutical group producing generics and branded products across multiple therapeutic categories; comparable to Zenith as a domestic Moroccan manufacturer with both proprietary and partnership-driven offerings.
• Cooper Pharma: One of the largest Moroccan pharmaceutical manufacturers with a broad generics portfolio across multiple therapeutic areas; directly comparable to Zenith in product breadth, domestic distribution model, and Moroccan market focus.

Regional players

• Medis (Tunisia): Tunisian pharmaceutical manufacturer with a broad generics portfolio serving Maghreb and African markets; comparable to Zenith in regional Maghreb presence, generics focus, and multi-therapeutic area strategy.
• Adcock Ingram: South African pharmaceutical manufacturer and distributor with broad prescription, OTC, and generics portfolio; comparable to Zenith in emerging-market pharma manufacturing scale and multi-channel distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/zenithpharmasa
• LinkedInlinkedin.com/company/zenithpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zenith Pharma